The company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-PD-...
EAGAN, Minn., Nov. 13, 2017 (GLOBE NEWSWIRE) --Biotheraannounced today the presentation of clinical and preclinical research supporting the mechanism of action for the Company’s cancer immunotherapy Imprime PGG, which is currently being evaluated in combination with immune checkpoint ...
Patient genomic and clinical data for various cancer types such as colorectal adenocarcinoma and pancreatic adenocarcinoma were collected for prognostic biomarker analysis.RESULTS: In the in vivo efficacy study of single and combination treatment with Keytruda and MBG453, we observed that NK cells were ...
Both PD-L1 and PD-L2 ligands interact with PD-1 in a cross- competitive fashion and hence PD-1 inhibitors block the interaction of PD-L1 and PD-L2 with PD-1 simultaneously and antagonize PD-1/PD-L1 and PD-1/PD-L2 axes completely [6,33]. Pembrolizumab (Keytruda) and Nivolumab (...
Based on the results of one phase III multicenter trial, Keytruda is superior to chemotherapy in the first-line treatment of MSI-H or dMMR CRC, resulting in longer PFS and fewer treatment-related adverse events.384 Other potential therapies Current chemotherapy for CRLM is still not desirable ...
Colorectal cancer (CRC) is one of the most frequently occurring malignancy tumors with a high morbidity additionally, CRC patients may develop liver metastasis, which is the major cause of death. Despite significant advances in diagnostic and therapeutic
The company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-...